Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Average NHI-Market Price Gap at 8.0%: MHLW
December 2, 2020
- Japan’s Healthcare Spend Rises to 43.4 Trillion Yen in FY2018
December 2, 2020
- MHLW Approves Label Expansions for Forxiga, Trelegy, Evrenzo, Cabometyx and More
November 30, 2020
- Ono’s Cancer Cachexia Drug to Finally Come Up for PAFSC Review on Dec. 11
November 30, 2020
- MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
November 30, 2020
- CEFP Member Urges Off-Year Re-Pricing for Preferably All Products, At Least 80%
November 30, 2020
- Japan to Set New Generic Target by March-End: Health Minister
November 30, 2020
- ICH to Stick to Urgent Topics with Significant Impact for Now amid COVID-19
November 30, 2020
- Orphan Drug Status Granted for Lilly’s Selpercatinib, 6 More APIs
November 27, 2020
- Japan Diet Expected to Enact Immunization Bill on Dec. 2
November 27, 2020
- COVID-19 Vaccines Not Actively Recommended for Children: Professor
November 27, 2020
- Second CAR-T Therapy Yescarta Up for Panel Review; MHLW to Report Corrective Measures for Zolgensma Issue
November 27, 2020
- LDP Health Policy Clique Set to Urge Govt to Skip Off-Year Re-Pricing Next Year, but Explore Middle Ground at Same Time
November 27, 2020
- PM Says to Get COVID-19 Shot When His Turn Comes Around
November 26, 2020
- MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
- 3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”
November 26, 2020
- MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
- JPMA Concerned about COVID-19 Pandemic’s Impact on Efforts to Improve Distribution
November 26, 2020
- MHLW Formulates Package Strategy for SaMD Commercialization, Eyes Sakigake Scheme
November 26, 2020
- Drug Price Negotiations in 1st Half Delayed by COVID-19 Impact: JPWA Survey
November 25, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…